Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Dose-Response Study Comparing Rapid Acting Intramuscular Olanzapine and Intramuscular Placebo in Agitated Patients With Schizophrenia

NCT00316238 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00316238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00316238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Dose-Response Study Comparing Rapid Acting Intramuscular Olanzapine and Intramuscular Placebo in Agitated Patients With Schizophrenia
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
May 31, 2007
Enrollment
160 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia